Aclarion Announces Commercial Agreement with Spine Institute of Louisiana
Aclarion (NASDAQ: ACON) has signed a commercial agreement with the Spine Institute of Louisiana (SIL), expanding its Nociscan technology to Louisiana. This marks Aclarion's first customer using Philips MR Spectroscopy (MRS), demonstrating the platform's integration capabilities across multiple systems.
Nociscan, a SaaS platform that helps physicians identify chronic low back pain sources, is now available at 17 sites across eight states and four countries. The technology boasts a 97% surgical success rate when treating all Nociscan-identified pain-positive discs.
Key highlights:
- SIL brings five board-certified, fellowship-trained surgeons to the partnership
- The institute has a research facility established in 2005 with national recognition
- Nociscan uses biomarkers and AI algorithms to noninvasively distinguish between painful and nonpainful discs
- The technology addresses a global healthcare challenge affecting approximately 266 million people with degenerative spine disease and low back pain
Aclarion (NASDAQ: ACON) ha firmato un accordo commerciale con il Spine Institute of Louisiana (SIL), ampliando la sua tecnologia Nociscan in Louisiana. Questo rappresenta il primo cliente di Aclarion che utilizza la spettroscopia MR di Philips (MRS), dimostrando la capacità della piattaforma di integrarsi con diversi sistemi.
Nociscan, una piattaforma SaaS che aiuta i medici a identificare le cause del dolore cronico alla parte bassa della schiena, è ora disponibile in 17 sedi distribuite in otto stati e quattro paesi. La tecnologia vanta un tasso di successo chirurgico del 97% nel trattamento di tutti i dischi positivi al dolore identificati da Nociscan.
Punti salienti:
- SIL contribuisce con cinque chirurghi certificati e specializzati
- L’istituto dispone di una struttura di ricerca fondata nel 2005 con riconoscimento nazionale
- Nociscan utilizza biomarcatori e algoritmi di intelligenza artificiale per distinguere in modo non invasivo tra dischi dolorosi e non dolorosi
- La tecnologia affronta una sfida globale della sanità che riguarda circa 266 milioni di persone affette da malattie degenerative della colonna vertebrale e dolore lombare
Aclarion (NASDAQ: ACON) ha firmado un acuerdo comercial con el Spine Institute of Louisiana (SIL), expandiendo su tecnología Nociscan a Louisiana. Este es el primer cliente de Aclarion que utiliza la espectroscopía MR de Philips (MRS), demostrando la capacidad de integración de la plataforma en múltiples sistemas.
Nociscan, una plataforma SaaS que ayuda a los médicos a identificar las fuentes del dolor lumbar crónico, está ahora disponible en 17 sitios en ocho estados y cuatro países. La tecnología cuenta con una tasa de éxito quirúrgico del 97% al tratar todos los discos positivos al dolor identificados por Nociscan.
Puntos clave:
- SIL aporta cinco cirujanos certificados y con formación especializada
- El instituto cuenta con una instalación de investigación establecida en 2005 con reconocimiento nacional
- Nociscan utiliza biomarcadores y algoritmos de IA para distinguir de forma no invasiva entre discos dolorosos y no dolorosos
- La tecnología aborda un desafío global de salud que afecta aproximadamente a 266 millones de personas con enfermedad degenerativa de la columna y dolor lumbar
Aclarion (NASDAQ: ACON)은 Spine Institute of Louisiana (SIL)와 상업 계약을 체결하여 루이지애나에 Nociscan 기술을 확장했습니다. 이는 Aclarion이 Philips MR 분광법(MRS)을 사용하는 첫 고객으로, 플랫폼이 여러 시스템에 통합될 수 있음을 보여줍니다.
Nociscan은 만성 요통의 원인을 식별하는 데 도움을 주는 SaaS 플랫폼으로, 현재 8개 주 17개 지점과 4개국에서 이용 가능합니다. 이 기술은 Nociscan이 확인한 통증 양성 디스크를 치료할 때 97%의 수술 성공률을 자랑합니다.
주요 내용:
- SIL은 5명의 전문 자격을 갖춘 외과의를 파트너로 참여시킴
- 2005년에 설립되어 국가적으로 인정받은 연구 시설 보유
- Nociscan은 바이오마커와 AI 알고리즘을 사용해 통증이 있는 디스크와 없는 디스크를 비침습적으로 구분
- 이 기술은 약 2억 6,600만 명이 겪는 퇴행성 척추 질환 및 요통이라는 전 세계 보건 문제를 해결
Aclarion (NASDAQ : ACON) a signé un accord commercial avec le Spine Institute of Louisiana (SIL), étendant ainsi sa technologie Nociscan en Louisiane. Il s'agit du premier client d'Aclarion utilisant la spectroscopie RM de Philips (MRS), démontrant la capacité de la plateforme à s'intégrer à plusieurs systèmes.
Nociscan, une plateforme SaaS qui aide les médecins à identifier les sources de douleurs lombaires chroniques, est désormais disponible sur 17 sites répartis dans huit États et quatre pays. La technologie affiche un taux de réussite chirurgicale de 97 % lors du traitement de tous les disques douloureux identifiés par Nociscan.
Points clés :
- SIL apporte cinq chirurgiens certifiés et formés en fellowship à ce partenariat
- L'institut dispose d'un centre de recherche établi en 2005 et reconnu au niveau national
- Nociscan utilise des biomarqueurs et des algorithmes d'IA pour distinguer de manière non invasive les disques douloureux des disques non douloureux
- La technologie répond à un défi mondial de santé touchant environ 266 millions de personnes souffrant de maladies dégénératives de la colonne vertébrale et de douleurs lombaires
Aclarion (NASDAQ: ACON) hat eine kommerzielle Vereinbarung mit dem Spine Institute of Louisiana (SIL) unterzeichnet und erweitert damit seine Nociscan-Technologie nach Louisiana. Dies ist Aclarions erster Kunde, der Philips MR-Spektroskopie (MRS) nutzt, und zeigt die Integrationsfähigkeit der Plattform über verschiedene Systeme hinweg.
Nociscan, eine SaaS-Plattform, die Ärzten hilft, die Ursachen chronischer Rückenschmerzen zu identifizieren, ist jetzt an 17 Standorten in acht Bundesstaaten und vier Ländern verfügbar. Die Technologie weist eine chirurgische Erfolgsquote von 97 % bei der Behandlung aller von Nociscan identifizierten schmerzhaften Bandscheiben auf.
Wichtige Highlights:
- SIL bringt fünf fachärztlich zertifizierte und fellowship-ausgebildete Chirurgen in die Partnerschaft ein
- Das Institut verfügt über eine 2005 gegründete Forschungseinrichtung mit nationaler Anerkennung
- Nociscan nutzt Biomarker und KI-Algorithmen, um schmerzhafte von schmerzfreien Bandscheiben nichtinvasiv zu unterscheiden
- Die Technologie adressiert eine globale Gesundheitsherausforderung, die etwa 266 Millionen Menschen mit degenerativen Wirbelsäulenerkrankungen und Rückenschmerzen betrifft
- Expanded commercial presence to 17 sites across 8 states and 4 countries, showing market penetration growth
- Successfully integrated Nociscan with Philips MR Spectroscopy platform, demonstrating technology compatibility
- Partnership with prestigious Spine Institute of Louisiana, adding credibility and market reach
- 97% surgical success rate reported when using Nociscan for disc pain identification
- No financial terms or revenue projections disclosed from the new commercial agreement
- Operating in a highly competitive medical device market with established players
Insights
Aclarion expands Nociscan to Louisiana with SIL partnership, demonstrates cross-platform compatibility with Philips MRS systems.
The commercial agreement between Aclarion and the Spine Institute of Louisiana (SIL) marks strategic expansion of Aclarion's Nociscan platform, bringing their total presence to 17 commercial sites spanning eight states and four countries. This partnership represents Aclarion's entry into the Louisiana market and adds a nationally recognized spine center to their client roster.
A technically significant aspect of this expansion is that SIL represents Aclarion's first customer using Philips MR Spectroscopy (MRS), demonstrating Nociscan's integration capability across multiple MRS platforms. This cross-platform compatibility potentially reduces a technical barrier to adoption for facilities with various existing MR infrastructure.
The partnership with SIL, which features five board-certified, fellowship-trained surgeons who treat spinal disorders, brings clinical credibility to Nociscan. SIL has established a research institute that has garnered national and international recognition, suggesting the center maintains rigorous clinical standards.
According to the article, Nociscan addresses the chronic low back pain (cLBP) market, which affects approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Nociscan is described as "the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine." The article states that when used with other diagnostic tools, Nociscan demonstrates a 97% surgical success rate when Nociscan-identified pain-positive discs are treated.
While no financial terms are disclosed, this partnership appears to represent continued execution of Aclarion's commercialization strategy.
Nociscan's biomarker technology for chronic back pain diagnosis expands to SIL, showing clinical utility across MR platforms.
The Spine Institute of Louisiana (SIL) adopting Aclarion's Nociscan technology represents clinical expansion of a diagnostic approach for chronic low back pain (cLBP) that objectively quantifies chemical biomarkers associated with disc pain. From a clinical perspective, this technology addresses a significant diagnostic challenge in spine medicine – accurately identifying which discs are sources of pain.
Traditional diagnostic methods for discogenic pain have limitations in specificity and often rely on subjective patient reporting or invasive procedures. Nociscan's approach, using MR Spectroscopy to non-invasively identify chemical biomarkers, represents an evidence-based addition to the clinical toolkit for spine specialists.
The technical compatibility with Philips MRS systems, mentioned as the first such customer integration, demonstrates interoperability across different MR platforms. This flexibility could be clinically important for adoption as it suggests the technology can integrate with existing infrastructure at various healthcare facilities.
The article cites a 97% surgical success rate when all Nociscan-identified pain-positive discs are treated, though details of this clinical evidence (study size, methodology, control group) aren't provided. If validated through peer-reviewed research, this success rate would represent a meaningful improvement over typical outcomes in spinal intervention.
SIL's reputation as a center with a research institute that has received national and international recognition suggests they maintain high clinical standards for technology adoption. Their implementation of Nociscan aligns with their stated commitment to "innovative and less invasive techniques to treat patients suffering from chronic low back pain."
The global scale of cLBP affecting 266 million people underscores the clinical significance of improved diagnostic tools in this field.
Expands access to first customer using Philips MR Spectroscopy (MRS), demonstrating ease of Nociscan integration across multiple MRS platforms
Nociscan now commercially available at 17 sites covering eight states and four countries
BROOMFIELD, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established a commercial agreement with the Spine Institute of Louisiana (SIL) in Shreveport, LA. The agreement brings Nociscan to Louisiana and the leading spine physicians of SIL who have earned a national reputation for innovation and excellence.
“SIL has a long tradition of adopting innovative and less invasive techniques to treat patients suffering from chronic low back pain and Nociscan is a natural extension of this commitment,” said Pierce Nunley, MD, Orthopedic Surgeon at SIL. “It’s often difficult to pinpoint the true source of chronic low back pain. The clinical evidence supporting Nociscan highlights the important role it plays as a decision support tool and a new hope for those who struggle with persistent back pain.”
SIL has five board-certified, fellowship-trained surgeons who treat spinal disorders surgically and non-surgically using innovative tools like Nociscan. In 2005, SIL established a research institute that has won many prestigious awards and received national and international recognition. For more information about SIL, please visit: Spine Institute of Louisiana.
The addition of SIL in Louisiana brings the total number of commercial centers where Nociscan is available to 17, covering eight states and four countries.
“Dr. Nunley and his SIL colleagues are true leaders in the spine industry, and we are pleased they will begin using Nociscan to advance their understanding of low back pain and personalized treatment options for patients,” said Brent Ness, Chief Executive Officer of Aclarion. “The use of Nociscan with our first customer using Philips MRS showcases how seamlessly our technology integrates across platforms and highlights our commitment to ensuring our customers have the best solutions available to meet their needs.”
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain and demonstrates a
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contact:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
FAQ
How many locations now offer Aclarion's Nociscan technology for back pain diagnosis?
What is the success rate of surgeries using Aclarion (ACON) Nociscan for back pain treatment?
How does Aclarion's Nociscan technology work with Philips MR Spectroscopy?
What is the market potential for Aclarion's (ACON) back pain diagnostic technology?
How does Aclarion (ACON) Nociscan help doctors diagnose chronic back pain?
